Japanese pharma giant M/S Astellas Pharma announced (in a press release Here ) that they have initiated the patent infringement action against generic pharma gaint M/S Teva pharma in United States District Court, Southern District of New York on September 22, 2009.
Following patent is listed in the Orange Book for Solifenacin Succinate (Vesicare) 5 and 10 mg tablets:
US6017927 (Assignee: Yamanouchi Pharmaceutical; Date of Expiry: Nov 19, 2018): The patent covers quinuclidine derivatives or their salts, or quaternary ammonium salts having muscarinic receptor antagonistic activities and also to pharmaceutical compositions containing such compounds. The patent covers Solifenacin as product.
Solifenacin Succinate (Vesicare) tablets are prescribed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.
Innvator Asttelas has been marketing Solifenacin Succinate (Vesicare) 5 and 10 mg tablets, since Nov 19, 2004
No comments:
Post a Comment